Research and Markets has announced the addition of the "Protein Phosphatase 2A (PP2A or EC 220.127.116.11) - Pipeline Review, H2 2016" report to their offering.
Protein Phosphatase 2A (PP2A or EC 18.104.22.168) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. Our latest report Protein Phosphatase 2A (PP2A or EC 22.214.171.124) - Pipeline Review, H2 2016, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Protein Phosphatase 2A (PP2A or EC 188.8.131.52) Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively.
Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 184.108.40.206) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/mhbtdx/protein
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005869/en/Business Wire
Last updated on: 12/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.